Viking Therapeutics VKTX Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's net unrealized gains (losses) on securities still held?
- Viking Therapeutics (VKTX) reported net unrealized gains (losses) on securities still held of -$1.25M in Q1 2026.
- How has Viking Therapeutics's net unrealized gains (losses) on securities still held changed year-over-year?
- Viking Therapeutics's net unrealized gains (losses) on securities still held decreased by 322.0% year-over-year, from $563K to -$1.25M.
- What is the long-term trend for Viking Therapeutics's net unrealized gains (losses) on securities still held?
- Over 3 years (2021 to 2025), Viking Therapeutics's net unrealized gains (losses) on securities still held has grown at a 31.6% compound annual growth rate (CAGR), from -$495K to $1.13M.
- What does net unrealized gains (losses) on securities still held mean?
- This metric captures the change in the fair value of investment securities held by the company that have not yet been sold. It reflects unrealized gains or losses that are excluded from net income but are recognized as part of comprehensive income. Tracking this provides insight into the volatility and performance of the company's investment portfolio.